CN107213254A - Purposes of the Compound Xueshuantong preparation in the treatment disease mediated medicines of PAF are prepared - Google Patents
Purposes of the Compound Xueshuantong preparation in the treatment disease mediated medicines of PAF are prepared Download PDFInfo
- Publication number
- CN107213254A CN107213254A CN201710453274.XA CN201710453274A CN107213254A CN 107213254 A CN107213254 A CN 107213254A CN 201710453274 A CN201710453274 A CN 201710453274A CN 107213254 A CN107213254 A CN 107213254A
- Authority
- CN
- China
- Prior art keywords
- paf
- treatment
- compound xueshuantong
- purposes
- xueshuantong preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000009277 Panax notoginseng extract Substances 0.000 title claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 15
- 201000010099 disease Diseases 0.000 title claims abstract description 14
- 150000001875 compounds Chemical class 0.000 title claims abstract description 13
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 230000001404 mediated effect Effects 0.000 title claims abstract description 6
- 229940079593 drug Drugs 0.000 title description 4
- 108010003541 Platelet Activating Factor Proteins 0.000 claims abstract description 35
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 claims abstract description 34
- 208000025865 Ulcer Diseases 0.000 claims abstract description 4
- 208000006673 asthma Diseases 0.000 claims abstract description 4
- 231100000397 ulcer Toxicity 0.000 claims abstract description 4
- 206010014561 Emphysema Diseases 0.000 claims abstract description 3
- 208000009525 Myocarditis Diseases 0.000 claims abstract description 3
- 230000001154 acute effect Effects 0.000 claims abstract description 3
- 210000000496 pancreas Anatomy 0.000 claims 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 206010033645 Pancreatitis Diseases 0.000 abstract description 3
- 206010033647 Pancreatitis acute Diseases 0.000 abstract description 3
- 201000003229 acute pancreatitis Diseases 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 3
- 239000007924 injection Substances 0.000 abstract description 3
- 238000002347 injection Methods 0.000 abstract description 3
- 239000005457 ice water Substances 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 12
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 9
- 210000004623 platelet-rich plasma Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 108700023400 Platelet-activating factor receptors Proteins 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000002525 phosphocholine group Chemical class OP(=O)(OCC[N+](C)(C)C)O* 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 102000030769 platelet activating factor receptor Human genes 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 210000001957 retinal vein Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Present invention firstly discloses purposes of the Compound Xueshuantong preparation in the disease medicament for preparing treatment PAF mediations.The rat acute qi depression to blood stasis model experiment that the present invention is induced by using ice-water bath joint injection adrenaline is proved, Compound Xueshuantong preparation can significantly inhibit platelet activating factor (PAF) activity, have significant curative effect to the relevant disease for the treatment of PAF mediations.The treatment of the diseases such as the myocarditis, asthma, pulmonary emphysema, acute pancreatitis or the gastroenteritic ulcer that are particularly mediated by PAF.
Description
Technical field
The present invention relates to the new application of Compound Xueshuantong preparation, especially in the disease medicament for preparing treatment PAF mediations
Purposes.
Background technology
Platelet activating factor (platelet-activating factor, PAF；1-O- alkyl -2- acetyl group-sn- is sweet
Oily -3 phosphocholines), it is a kind of lipid mediators with bioactivity, is also so far known most strong platelet activation
Agent.Internal many cells, such as acidophilus, basophilic, neutrophil cell, monocyte-macrophage, mast cell, blood platelet and endothelium are thin
Born of the same parents etc., can produce PAF, PAF has the biological activity similar to hormone in vivo, can act under certain condition stimulation
In various kinds of cell and tissue.Research shows that PAF can not only promote platelet aggregation, can also make neutrophil accumulation, cause
The release of oxygen radical, TNF, interleukin etc., so as to increase vasopermeability, causes microcirculation disorder and inflammatory
Reaction.Clinically, the disease such as PAF and angiocardiopathy, asthma, acute pancreatitis, gastroenteritic ulcer is closely related.At present, it is existing
The largely research on paf receptor antagonistses.Because substantial amounts of pathological immune and inflammatory reaction are mediated by PAF, find and suppress
The new medicine of PAF activity, which just seems, to be highly desirable to.
FUFANG XUESHUANTONG JIAONANG is the eighties in last century, limited by Zhongshan University's Eye Center and Guangdong all living creatures' medicine company share
The Chinese traditional compound medicine that company develops jointly, with promoting blood circulation and removing blood stasis, effect of supplementing qi and nourishing yin.FUFANG XUESHUANTONG JIAONANG by pseudo-ginseng,
The red sage root, the Radix Astragali, radix scrophulariae composition, its prescription has distinct traditional Chinese medical science Nan Pai administration features, clinically for blood stasis and deficiency of both qi and yin
The retinal vein obstruction and stability angina of effort of card.Patent document CN103655910A discloses Compound Xueshuantong glue
Capsule has liver protection.At present, it there is no the document report for suppressing PAF activity on FUFANG XUESHUANTONG JIAONANG.
The content of the invention
It is an object of the invention to provide use of the FUFANG XUESHUANTONG JIAONANG in the disease medicament for preparing treatment PAF mediations
On the way.
The rat acute qi depression to blood stasis model experiment that the present invention is induced by using ice-water bath joint injection adrenaline is demonstrate,proved
Bright, Compound Xueshuantong preparation can significantly inhibit platelet activating factor (PAF) activity, to the relevant disease for the treatment of PAF mediations
With significant curative effect.The diseases such as the myocarditis, asthma, pulmonary emphysema, acute pancreatitis or the gastroenteritic ulcer that are particularly mediated by PAF are equal
Has significant curative effect.
Compared with prior art, the disease for the treatment of PAF mediations is being prepared present invention firstly discloses Compound Xueshuantong preparation
Purposes in medicine.
Embodiment
With reference to specific embodiment, the present invention will be further described.
Embodiment 1
First, experimental animal and material
SPF grades of (specific-pathogen free) male SD (Sprague Dawley) rats 60, body weight 180-
220g, animal quality quality certification number：44007200028430；There is provided by Guangdong Medical Lab Animal Center, animal facility is permitted
Can the number of card：SCXK- (Guangdong) 2013-0002.
Adrenalin hydrochloride parenteral solution (Adrenaline, Adr；Shanghai Hefeng Pharmaceutical Co., Ltd., lot number：
20141009), physiological saline, sodium citrate, chloraldurate (Guangzhou Chemical Reagent Factory), platelet activating factor (Platelet
Activating factor, PAF) kit (Bioengineering Research Institute is built up in Nanjing).
2nd, test method
SD rats are randomly divided into 6 groups, i.e. blank control group, model group, positive control drug (aspirin) group, compound blood
Bolt leads to low dose group, Compound Xueshuantong middle dose group, Compound Xueshuantong high dose group, every group 10.Animal adapts in the environment
Start experiment after one week.Once, administered volume is 10ml/ for FUFANG XUESHUANTONG JIAONANG group and the daily gastric infusion of positive control drug group
Kg, successive administration 10 days.Blank control group and model group gavage give same volume physiological saline.11st day early morning, gastric infusion
After 1h, in addition to blank control group rat, remaining each group rat skin lower injection adrenalin hydrochloride (0.8mg/kg), by rat after 2h
Ice bath 5min in 0-4 DEG C of frozen water is placed in, blank control group rat does not make rat after leaching frozen water processing, 2h and hydrochloric acid is subcutaneously injected again
Adrenaline (0.8mg/kg).Isometric physiological saline is subcutaneously injected in blank control group.Water 12h is can't help in the equal fasting of each group rat.
Secondary morning, above-mentioned each group rat carries out intraperitoneal injection of anesthesia (0.35mL/100 g), 2% using 10% chloraldurate
Iodine carries out abdominal aorta blood sampling with abdominal cavity is opened after sterilization skin, and part blood is not added with anti-coagulants, centrifuges after serum, utilizes
ELISA determines kit detection platelet activating factor PAF, and kit builds up Bioengineering Research Institute by Nanjing and provided, by examination
The method that agent box is provided is determined.In addition, part blood is with sodium citrate anti-freezing, (3.2%, blood volume compares 1：9) 3.0mL, is taken to resist
Coagulableblood is put into TDL-5M refrigerated centrifuges progress first time centrifugation (500r/m, 20 DEG C, 10min) and obtains platelet rich plasma
(PRP), take out platelet rich plasma and remainder is centrifuged to (3000r/m, 20 DEG C, 10min) again and obtain platelet poor plasma
(PPP), 5 μ L ADP (300 μm of ol/L) are used for induced platelet aggregation, and 300 μ L PRP and 300 μ L PPP are put into Beijing Puli life
LBY-NJ4 platelet aggregation instruments detection maximum platelet aggregation rate (MPAR).
3rd, experimental result
From table 1, compared with blank control group, model group rats PAF contents are significantly raised, and platelet aggregation rate also shows
Write rise.The basic, normal, high dosage group P of Rats AF contents of FUFANG XUESHUANTONG JIAONANG and platelet aggregation rate drop more notable than model group
Low, difference is respectively provided with statistical significance (P<0.01 or P<0.05), and in a certain amount relation is imitated.As a result illustrate, aspirin
Suppression to platelet aggregation rate is not related to platelet activating factor (PAF), and FUFANG XUESHUANTONG JIAONANG is to platelet aggregation
The inhibitory action of rate may be related to suppressing PAF, that is, find that FUFANG XUESHUANTONG JIAONANG has and suppress this new application of PAF, be it
Application in the disease medicament for preparing treatment PAF mediations provides foundation.
Influence of the FUFANG XUESHUANTONG JIAONANG of table 1 to PAF and platelet aggregation rate
Note：*P<0.05and**P<0.01vs normal groups, #P<0.05and##P<0.01vs model groups (n=10).
Claims (2)
1. application of the Compound Xueshuantong preparation in treatment mediated by platelet activating factor disease medicament is prepared.
2. application as claimed in claim 1, it is characterized in that：Described disease includes myocarditis, asthma, pulmonary emphysema, acute pancreas
Adenositis or gastroenteritic ulcer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710453274.XA CN107213254A (en) | 2017-06-15 | 2017-06-15 | Purposes of the Compound Xueshuantong preparation in the treatment disease mediated medicines of PAF are prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710453274.XA CN107213254A (en) | 2017-06-15 | 2017-06-15 | Purposes of the Compound Xueshuantong preparation in the treatment disease mediated medicines of PAF are prepared |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107213254A true CN107213254A (en) | 2017-09-29 |
Family
ID=59949614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710453274.XA Pending CN107213254A (en) | 2017-06-15 | 2017-06-15 | Purposes of the Compound Xueshuantong preparation in the treatment disease mediated medicines of PAF are prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107213254A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022027898A1 (en) * | 2020-08-06 | 2022-02-10 | 汪炬 | Use of fgfr2b inhibitory molecule in preparation of medicament for treating paf-mediated diseases |
-
2017
- 2017-06-15 CN CN201710453274.XA patent/CN107213254A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022027898A1 (en) * | 2020-08-06 | 2022-02-10 | 汪炬 | Use of fgfr2b inhibitory molecule in preparation of medicament for treating paf-mediated diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102153668B (en) | Anticancer Armillaria luteovirens polysaccharide and extraction process thereof | |
| CN101073332A (en) | Lipid-lowering biscuit | |
| CN103816280B (en) | Traditional Chinese medicine composition for treating myocardial infarction and application of traditional Chinese medicine composition | |
| CN102225120A (en) | Medicine for treating fatty liver and preparation method thereof | |
| CN102600423A (en) | Preparation method of Chinese medicine for treating hepatic fibrosis | |
| CN104873491B (en) | The application of deoxyschizandrin, schisandrin C in anti-hepatic fibrosis medicines are prepared | |
| CN109045035B (en) | Application of 7- (2, 2-dimethyl-3-butenamido) -octahydro phenylquinoline acetate in preparation of medicine for treating liver diseases | |
| CN116570612B (en) | Pharmaceutical composition for improving microcirculation disturbance | |
| CN102526423A (en) | Medicine composition for treating ischemic heart disease | |
| CN102283859B (en) | Application of dicliptera chinensis polysaccharide | |
| CN107998161A (en) | A kind of pharmaceutical composition prevented and treat cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN107213254A (en) | Purposes of the Compound Xueshuantong preparation in the treatment disease mediated medicines of PAF are prepared | |
| CN114404462B (en) | Composition and application thereof in preparation of medicine for treating gastric injury and/or gastric ulcer | |
| CN103405501B (en) | Preparation method of three-component blood-activating and stasis-dissolving capsules | |
| CN105012826A (en) | Alpinia oxyphylla leaf extract and preparation method and application thereof | |
| CN105796625A (en) | Pharmaceutical composition containing red yeast rice and safflower and preparation thereof | |
| CN108065393A (en) | A kind of food or health food prevented and treat cardiovascular and cerebrovascular disease | |
| CN101032534B (en) | Method of preparing Ilex rotunda Thunb total saponins and the application thereof | |
| CN1733070A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN103156106A (en) | Lipid lowering and liver protecting drug or health food prepared by active ingredients of fructus schisandrae chinensis and preparation method | |
| CN106620470A (en) | Anti-fatigue traditional Chinese medicine composition delaying senescence | |
| CN105768095A (en) | Health food composition for improving immunity and preparation thereof | |
| CN102670956A (en) | Application of Chinese medicinal composition to preparation of anti-myocardial cell apoptosis and/or anti-myocardial cell apoptosis related disease drug | |
| CN101711793A (en) | Medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN101244041B (en) | Medicament for preventing and treating acute liver damnification and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170929 |
|
| RJ01 | Rejection of invention patent application after publication |